DBL Potassium Dihydrogen Phosphate Special Precautions

Phosphate should be administered with caution in conditions where high phosphate levels may be encountered, such as hypoparathyroidism, chronic renal disease, and rhabdomyolysis.
Phosphate should be administered with caution in conditions where low calcium levels may be encountered, such as hypoparathyroidism, osteomalacia, chronic renal disease, acute pancreatitis, rhabdomyolysis and rickets.
DBL Potassium Dihydrogen Phosphate Concentrated Injection should be administered with caution in conditions where high potassium levels may be encountered, such as acute dehydration, pancreatitis, rhabdomyolysis, severe renal insufficiency and extensive tissue damage (such as severe burns).
DBL Potassium Dihydrogen Phosphate Concentrated Injection should be administered with caution in patients with myotonia congenita, and heart disease (particularly in digitalised patients) (see Interactions) since these conditions may be exacerbated by the potassium in the injection.
Effects on laboratory tests: Saturation of bone binding sites by phosphate ions may cause decreased bone uptake of technetium Tc^99m labelled contrast agents in bone imaging.
Effects on Ability to Drive and Use Machines: The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.
Use in Children: No data available.
Use in the elderly: No data available.